Inserting end-modified DNA fragments with CRISPR-Cas9 yields highest efficiency
Evonetix’s technology utilises a silicon chip, made by MEMS processing, that controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches. Under the terms of the collaboration, imec will work with Evonetix to scale up manufacturing of the MEMS technology on 8-inch silicon wafers, enabling Evonetix to supply customers in volume. imec is able to leverage its experience in manufacturing silicon for life sciences applications to transfer the novel Evonetix process to their foundries and to manage further expansion in volume.
Dr Matthew Hayes, Chief Technology Officer at Evonetix, said:
With the support of imec, a world-renowned leader in microchip technology, we will be able to optimize our highly parallel desktop platform for commercial supply.”
Peter Peumans, VP Life Science Technologies at imec added:
We have extensive practical knowledge of chip design and technology, which we use to help develop innovative tools for the life sciences and pharma R&D. Evonetix has developed an innovative approach that integrates physics and biology to enable the production of high-fidelity long DNA in a highly parallel fashion. We are eager to contribute to their success using our nanotechnology capabilities.” Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology